February 15, 2018
Shareholders of Bioverativ Inc. slapped the biopharmaceutical company and its board of directors with a proposed securities class action in Massachusetts federal court on Thursday, accusing them of withholding crucial information needed to make an informed decision on a proposed $11.6 billion sale to Sanofi.